Compare RACE & ELV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RACE | ELV |
|---|---|---|
| Founded | 1947 | 1944 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.2B | 76.5B |
| IPO Year | 2015 | 2001 |
| Metric | RACE | ELV |
|---|---|---|
| Price | $332.62 | $290.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 18 |
| Target Price | ★ $488.14 | $383.65 |
| AVG Volume (30 Days) | 575.5K | ★ 1.9M |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | 1.02% | ★ 2.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 25.21 |
| Revenue | N/A | ★ $199,125,000,000.00 |
| Revenue This Year | $7.64 | N/A |
| Revenue Next Year | $7.41 | $3.10 |
| P/E Ratio | $34.59 | ★ $11.42 |
| Revenue Growth | N/A | ★ 12.49 |
| 52 Week Low | $328.00 | $273.71 |
| 52 Week High | $519.10 | $458.75 |
| Indicator | RACE | ELV |
|---|---|---|
| Relative Strength Index (RSI) | 34.39 | 36.63 |
| Support Level | $328.00 | $274.06 |
| Resistance Level | $381.03 | $322.45 |
| Average True Range (ATR) | 7.53 | 10.64 |
| MACD | -4.19 | -1.11 |
| Stochastic Oscillator | 3.55 | 25.46 |
Ferrari designs, engineers, and manufactures some of the world's most expensive luxury cars. With supply carefully controlled to be below demand and a brand steeped in decades of motor racing history, a Ferrari is viewed as a status symbol. In 2025, the company sold 13,640 vehicles at an average price over EUR 500,000 with more than 80% of its vehicles being sold to existing Ferrari clients. Eighty-four percent of revenue is generated from the sale of cars and spare parts and 10% from sponsorship, commercial, and brand activities including racing and lifestyle activities. In 2025, the Europe, Middle East, and Africa region accounted for 49% of revenue, the Americas was 32%, mainland China, Hong Kong, and Taiwan was 7%, and the rest of Asia was 12%.
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of June 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.